Anti-VEGF Treatment Strategies for Wet AMD by Kovach, Jaclyn L. et al.
Hindawi Publishing Corporation
Journal of Ophthalmology
Volume 2012, Article ID 786870, 7 pages
doi:10.1155/2012/786870
Review Article
Anti-VEGFTreatmentStrategiesforWetAMD
Jaclyn L.Kovach,1 Stephen G. Schwartz,1 HarryW. FlynnJr.,1 andIngridU.Scott2
1Department of Ophthalmology, Bascom Palmer Eye Institute, School of Medicine, University of Miami,
311 9th St North, Naples, FL 34102, USA
2Penn State Hershey Eye Center, Hershey, PA 17033, USA
Correspondence should be addressed to Jaclyn L. Kovach, jkovach@med.miami.edu
Received 1 July 2011; Revised 20 September 2011; Accepted 23 October 2011
Academic Editor: James T. Handa
Copyright © 2012 Jaclyn L. Kovach et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular
age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to
individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.
1.Introduction
Age-related macular degeneration (AMD) is the result of
complex interactions between lipofuscinogenesis, druseno-
genesis, and inﬂammation which can lead to choroidal neo-
vascularization (CNV). Unregulated choroidal angiogenesis
begins when local inﬂammation, and potentially ischemia,
disrupt a delicate interplay between numerous stimulators
and inhibitors, which may lead to an imbalance between the
proangiogenic vascular endothelial growth factor (VEGF)
and the antiangiogenic pigment epithelium-derived factor
(PEDF) [1]. VEGF-A plays an important role in angiogenesis
and vascular permeability. The VEGF-A gene is organized
into eight exons on chromosome 6p21. Alternate gene
splicing can generate 9 isoforms, the most prevalent of which
is VEGF165. VEGF-A (or VEGF as it is commonly known)
is a dimeric glycoprotein that interacts with two tyrosine
kinase receptors, VEGFR-1 and VEGFR-2 located primarily
on endothelial cells [2].
Animal studies have demonstrated that VEGF overex-
pression in the retinal pigment epithelium (RPE) leads to
CNV [3]. In a monkey model of laser-induced CNV, in-
travitreal injections of an anti-VEGF-A antibody prevented
the development of CNV and reduced leakage from preex-
isting CNV [4], and intravitreal injections of ranibizumab
(Lucentis; Genentech/Roche, South San Francisco) in com-
binationwithphotodynamictherapy(PDT)withverteporﬁn
(Visudyne; Novartis, Basel, Switzerland) decreased CNV
leakage and induced CNV regression [5].
Over the past few years, anti-VEGF therapy for neovas-
cular AMD has become a standard treatment for neovascular
AMD. This paper will review anti-VEGF treatment options
and current treatment strategies.
2.Pegaptanib
Pegaptanib (Macugen; Eyetech, Palm Beach Gardens, FL)
is a selective inhibitor of VEGF165. The Vascular Endothe-
lial Growth Factor (VEGF) Inhibition Study in Ocular
Neovascularization (VISION) Study included two con-
current, prospective, randomized, double-masked, dose-
ranging,controlledphaseIIIclinicaltrialsthatdemonstrated
that intravitreal administration of pegaptanib at 6-week
intervals for 48 weeks reduced the chance of moderate
and severe vision loss in patients with neovascular AMD
regardless of angiographic subtype of CNV. In the group
that was given the 0.3mg dose of pegaptanib, 70 percent of
patients lost fewer than 15 letters of visual acuity, compared
with 55 percent among the control group. More patients2 Journal of Ophthalmology
receiving 0.3mg pegaptanib compared to sham maintained
or gained visual acuity (33 percent versus 23 percent) [6].
Patients who continued on pegaptanib during the second
year of the VISION Study lost less visual acuity compared
to those who discontinued pegaptanib or remained on PDT
or no treatment [7].
3.Bevacizumab
Bevacizumab (Avastin; Genentech/Roche, South San Fran-
cisco)isafull-length,humanized,monoclonalantibodywith
two VEGF-A binding sites (Figure 1). In 2004, the antiangio-
genic eﬀects of bevacizumab led to its FDA approval for the
treatment of metastatic colon cancer [10]. A potential role
for bevacizumab in the treatment of AMD was established
when animal studies revealed that ﬂuorescein-conjugated
bevacizumab leaked from laser-induced CNV after systemic
administration to cynomolgus monkeys, suggesting that
systemic bevacizumab could leak from CNV in patients
with AMD and competitively inhibit extravascular VEGF
[11]. The Systemic Avastin for Neovascular AMD (SANA)
Study was an open label prospective clinical study that
evaluated the safety, eﬃcacy, and durability of bevacizumab
for the treatment of subfoveal CNV in AMD. Participants
were treated at baseline with an infusion of bevacizumab
(5mg/kg) followed by one or two additional doses at two-
week intervals. At 24 weeks, systemic bevacizumab was well
tolerated and associated with an average of a 14 letter gain in
the best-corrected visual acuity (BCVA) and a reduction in
central retinal thickness by 112 microns on optical coherence
tomography (OCT) in the 18 patients studied [12]. Large
clinical trials of intravenous bevacizumab were not pursued
due to the perception that intravitreal therapy would be a
safer alternative.
The ﬁrst reported case of bevacizumab injected into a
human eye was described in a 2005 case report of a
63-year-old woman with subfoveal, predominantly classic
CNV. Four weeks after a single-intravitreal injection of
bevacizumab (1mg), resolution of subretinal ﬂuid on OCT
was noted, and no adverse eﬀects were observed [13]. The
safety and eﬃcacy of intravitreal bevacizumab were inves-
tigated in a retrospective case series of 79 patients treated
with monthly bevacizumab (1.25mg) until resolution of
macular edema, subretinal ﬂuid, and/or pigment epithelial
detachment (PED) as observed on OCT. After two months,
intravitreal bevacizumab was well tolerated and associated
with an improvement in VA, decreased retinal thickness, and
a reduction in angiographic leakage in most patients, the
majority of whom had been treated previously with PDT
and/or pegaptanib [14].
In the years following these initial reports, the eﬃcacy
and tolerability of intravitreal bevacizumab was reported
by hundreds of articles. It has been a commonly held
belief by many clinicians that the eﬃcacy of intravitreal
bevacizumab and ranibizumab is comparable, with no clear
diﬀerence, between the two treatments for most patients
other than price; one intravitreal dose of ranibizumab is at
least 40 times the cost of bevacizumab. The 1-year results
of the Comparison of Age-Related Macular Degeneration
Treatment Trials (CATTs) will be discussed in detail later in
this monograph.
4.Ranibizumab
Ranibizumab is an antibody fragment that binds to and
inhibits all identiﬁed VEGF isoforms (Figure 1). It was engi-
neeredtohave100timesthebindingaﬃnityofbevacizumab,
despite having only a single-binding site. Given the absence
of the Fc segment, the antibody fragment was designed
to possess a shorter systemic half-life, improved retinal
penetration, and less of a theoretical inﬂammatory reaction
compared to bevacizumab [15].
Regarding a pharmokinetic comparison of bevacizumab
and ranibizumab, when injected into human vitreous, 1-
million-fold excess of either drug is present. The biologic
activity in the vitreous of nonvitrectomized eyes has been
demonstratedtolastbetween27and38daysafterintravitreal
injection of bevacizumab and 30 days after intravitreal injec-
tion of ranibizumab. The binding activity of bevacizumab
is less than ranibizumab after a single injection. Both drugs
penetrate the retina, but bevacizumab has a longer half-
life in vitreous (as documented in rabbits and calculated
in humans) and has been found in the serum and fellow
eye in rabbits following intravitreal injection [16, 17]. All
anti-VEGF agents administered intravitreally and in clinical
use today have been identiﬁed in the systemic circulation
[18, 19].
The phase III Minimally Classic/Occult Trial of the
Anti-VEGF Antibody Ranibizumab in the Treatment of
Neovascular Age-Related Macular Degeneration (MARINA)
Trial evaluated the eﬃcacy and safety of ranibizumab for the
treatment of minimally classic or occult with no classic CNV
associated with AMD. This 2-year, prospective randomized,
double-masked, sham-controlled trial enrolled 716 patients
from 96 sites in the United States. Patients were randomized
in a 1:1:1 ratio to receive intravitreal ranibizumab at a dose
of either 0.3mg or 0.5mg or sham injection monthly in one
eye for 2 years.
At 24 months, 92% of patients who received 0.3mg
of ranibizumab and 90% of patients who received 0.5mg
ranibizumab lost fewer than 15 letters, compared with
52.9% in the sham group. The proportion of patients who
gained at least 15 letters on the Early Treatment of Diabetic
Retinopathy Study (ETDRS) chart from baseline to 24
months was 33.3% in the 0.5mg group, 26.1% in the 0.3mg
group, and 3.8% in the sham group. The mean change in
ETDRS VA from baseline to 24 months was a gain of 6.6
letters in the 0.5mg group, a gain of 5.4 letters in the 0.3mg
group, and a loss of 14.9 letters in the sham-injection group
[20].
The Anti-VEGF Antibody for the Treatment of Predom-
inantly Classic Choroidal Neovascularization in Age-Related
Macular Degeneration (ANCHOR) Trial was a multicenter,
randomized double-blind trial that enrolled 423 patients to
compare the eﬃcacy and safety of ranibizumab and PDT
with verteporﬁn in patients with predominantly classic CNVJournal of Ophthalmology 3
Figure 1: Ranibizumab is a recombinant humanized monoclonal antibody fragment. Bevacizumab is a recombinant humanized IgG
antibody. Both bind to and inhibit all biologically active forms of VEGF-A and are derived from the same mouse monoclonal antibody.
Ranibizumab has been genetically engineered to bind with higher aﬃnity than bevacizumab (see [8]).
associated with neovascular AMD. Patients were assigned
randomly to receive either 0.3 or 0.5mg of ranibizumab
plus sham verteporﬁn or sham intravitreal injection plus
active verteporﬁn therapy. Ranibizumab or sham intravitreal
injections were given monthly, and the verteporﬁn or sham
was administered on day 0 and then as needed at months 3,
6, 9, and 12.
At 12 months, 94.3% of patients in the 0.3mg group and
96.4% in the 0.5mg group lost fewer than 15 letters from
baseline compared with 64.3% in the verteporﬁn group. The
proportion of patients who gained at least 15 letters from
baseline to 12 months was 40.3% in the 0.5mg group, 35.7%
in the 0.3mg group, and 5.6% in the verteporﬁn group. The
mean change in ETDRS visual acuity from baseline to 12
months was a gain of 8.5 letters in the 0.3mg group, a gain of
11.3 letters in the 0.5mg group, and a loss of 9.5 letters in the
verteporﬁn group [21]. Rates of serious ocular or systemic
adverse events were low in both trials [20, 21].
The results of these two trials documented dramatic
vision improvement with mandatory monthly dosing regi-
mens.Subsequently,thePIERandEXCITEphaseIIIbstudies
sought to determine the dosing regimen that yielded the
best VA outcomes while minimizing treatment burden. The
results of these two trials supported the increased eﬃcacy
of monthly ranibizumab and the importance of timely
treatment and demonstrated that regimented, quarterly
dosing does not yield desirable VA outcomes [22, 23].
5. IndividualizedAnti-VEGFTherapy
5.1. Ranibizumab: As-Needed Regimen. The Prospective
OCT Imaging of Patients with Neovascular AMD Treated
with Intraocular Ranibizumab (PrONTO) study was an
open-label, prospective, uncontrolled study that investigated
a variable-dosing regimen for the treatment of wet AMD
with intravitreal ranibizumab over two years. Thirty-seven
patients received 3 consecutive monthly injections of 0.5mg
ranibizumab and were then followed monthly and retreated
if there was an increase in OCT central retinal thickness
(CRT) of at least 100microns or a loss of best-corrected
ETDRS VA of 5 letters or more. During the second year, the
retreatment criteria were amended to include retreatment if
any qualitative increase in the amount of ﬂuid was detected
on OCT. At 24 months, mean visual acuity improved by 11
letters with an average of 9.9 injections. In the PrONTO
study, VA outcomes were comparable with those reported
in ranibizumab phase III clinical studies, but with fewer
intravitreal injections [24].
Results from the SAILOR (Safety Assessment of Intrav-
itreal Lucentis for age-related macular degeneration) study,
a Phase IIIb study of Lucentis (Ranibizumab, Genentech,
South San Francisco, Calif.) for patients with all subtypes
of new or recurrent active subfoveal wet AMD, suggest that
quarterly visits were insuﬃcient to monitor and capture
disease progression [25, 26].
The SUSTAIN trial assessed the safety and eﬃcacy of
ranibizumab in patients with subfoveal CNV secondary
to AMD using a dosing regimen individualized to patient
characteristics. This open-label study recruited patients
with subfoveal CNV secondary to AMD who were either
ranibizumab-na¨ ıve or had completed treatment with ra-
nibizumab or verteporﬁn PDT in the ANCHOR trial.
Patients received three consecutive monthly injections of
ranibizumab 0.3mg (or 0.5mg for the ANCHOR patients)
(the “loading phase”), followed by monthly monitoring
visits. Further treatment was administered if VA decreased4 Journal of Ophthalmology
by >5 letters or if central retinal thickness (CRT) increased
by >100µm. A total of 513 patients were enrolled into the
study and 69 patients who were ranibizumab-na¨ ıve have
completed 12 months of followup. Compared with baseline,
mean VA at month 12 increased by approximately 7 letters.
Over 12 months, the mean standard deviation (SD) number
of ranibizumab injections received by these ranibizumab-
na¨ ıve patients was 5.3 (2.2), including the three “loading”
injections. This study demonstrated that ﬂexible, guided
dosing with fewer ranibizumab injections and monthly
monitoring can maintain eﬃcacy outcomes in at least some
patients [26].
The HORIZON study was an open-label multicenter
extension study that included 853 patients (600 had been
previously treated with ranibizumab initially, 184 had
crossed over to treatment with ranibizumab, and 69 had not
been treated with ranibizumab) who had completed one of
the three 2-year, randomized, controlled trials of monthly
intravitreal ranibizumab treatment (MARINA, ANCHOR,
or FOCUS trial). Of 853 patients, two-year VA data were
available for 384. These patients could receive 0.5mg
ranibizumab at 30-day or longer intervals as needed. Of the
patients who received initial treatment with ranibizumab
during the ANCHOR, MARINA, and FOCUS trials, there
was a mean 10.2-letter increase in VA during the ﬁrst 2
years of the studies. Patients that did not receive anti-VEGF
therapy in the ANCHOR, MARINA, and FOCUS trials had
worse outcomes. During the ﬁrst year of the HORIZON
study and the third year of the original trials, there was a 5.1-
letter loss. The initial VA increase decreased by a mean of 8
letters with less frequent dosing in years 3 and 4. During the
asneededdosingphase,themeannumberofinjectionsinthe
group initially treated with ranibizumab was 3.6. Patients in
the treated crossover group received a mean of 4.2 injections.
The results of the HORIZON trial demonstrate that a delay
in the initiation of treatment is associated with poorer visual
outcomes and continued but less frequent dosing in years 3
and 4 was associated with visual decline [27].
The as-needed ranibizumab studies have their strengths
and weaknesses. For example, strengths of PRONTO and
SUSTAIN include monthly follow-up, but the PRONTO trial
has only a small cohort of patients. The SAILOR trial is the
largest, but mandated only quarterly followup visits. Overall,
these studies support frequent followup and individualized
retreatment to achieve the best visual acuity gains with
the as-needed treatment regimen as an alternative to the
traditional monthly treatments used in the ANCHOR and
MARINA trials.
5.2. Ranibizumab: Treat-and-Extend Regimen. The treat-
and-extend regimen was ﬁrst described by Freund et al. for
the treatment of retinal angiomatous proliferation with an
anti-VEGF agent. Treat-and-extend dosing regimen involves
increasing intervals between treatment up to 10 weeks as
long as no ﬂuid is present on OCT. If ﬂuid is present, the
interval between treatments is shortened. Of note, Engelbert
et al. ﬁrst treated patients with 3 loading doses [28]. The
treat-and-extend regimen can be quite variable in terms of
treatment criteria, which can include vision loss and macular
hemorrhage [28], and the length of time between treatment,
which can extend up to 12 weeks [29, 30]. To date, no large,
randomized, prospective trials have investigated the eﬃcacy
of the treat-and-extend regimen compared to the as-needed
protocol, although this strategy is used currently in clinical
practice.
Oubrahamet al. comparedtwo ranibizumab retreatment
strategies, as-needed and treat-and-extend, in a retrospective
review of 90 patients, 52 in the as-needed group, and 38
in the treat-and-extend group. Their treatment regimen
included 3 loading doses for the as-needed group. Macular
hemorrhage without ﬂuid on OCT was not part of their
retreatment criteria. They found that at one year, mean gain
in VA was greater in the treat-and-extend group than in the
as-needed group (+10.8 versus +2.3 letters, resp.). Eyes in
the treat-and-extend group received signiﬁcantly more mean
injections (7.8 versus 5.2). Patients in the as-needed group
were followed every 4-5 weeks. The number of follow-up
visits was similar in both groups (8.5 versus 8.8) [29].
Gupta et al. compiled a retrospective, interventional,
case series of 92 eyes managed with the treat-and-extend
ranibizumab regimen. After 2 years, 32% had gained at least
3 lines of vision and received 8.36 and 7.45 injections during
the ﬁrst and second years, respectively. The treat-and-extend
regimen was associated with fewer patient visits, injections,
and direct annual medical costs compared with monthly
injections [30].
5.3. Bevacizumab: As-Needed Regimen. T h eA B Ct r i a li sa
prospective, double-masked, multicenter, randomized-con-
trolled trial of 131 patients randomized to 3 loading doses
of bevacizumab at 6-week intervals followed by as-needed
treatment at six week intervals or an alternate treatment at
the start of the trial (PDT, pegaptanib, or sham). Thirty-two
percent of patients in the bevacizumab group gained at least
15 letters with a mean VA increase of 7 letters with a median
of7injections.Therewasameandecreaseof9.4lettersinthe
standard treatment group [31]. Several smaller, retrospective
studiesnoteasubstantialimprovementinVAwithaprotocol
of three loading doses and then retreatment based mostly on
OCT ﬁndings [32, 33].
Retrospective studies have demonstrated stabilization or
improvement in VA following as-needed treatment with
bevacizumab without a loading phase [34–36]. A prospec-
tive, open-label, nonrandomized clinical study reported a
mean VA gain of 8.6 letters in 51 eyes after their second
year of as-needed bevacizumab treatment with a mean of 1.5
injections given during year 2 [37].
5.4. Bevacizumab: Treat-and-Extend Regimen. Gupta et al.
reviewed 166 eyes of 159 patients in a retrospective case
series of patients treated with a treat-and-extend regimen of
bevacizumab or ranibizumab for an average followup of 1.5
years. Patients had received monthly injections until dry on
OCT. Treatment intervals were extended by 2 weeks at a time
unless ﬂuid was observed on OCT. Visual acuity outcomes
and recurrence rates were similar for patients who received
ranibizumab or bevacizumab. At 1 year, 32–35% of patientsJournal of Ophthalmology 5
(a) (b)
Figure 2: (a) A binding domain of VEGFR1 and VEGFR2 are fused to create 2 dual-domain arms for each VEGF Trap-Eye molecule. (b)
The Fc portion of the IgG is fused to the two dual-domain arms to create the VEGF Trap-Eye molecule (see [9]).
gained at least 3 lines of vision and 45–52% of patients had
norecurrenceover1.5years.Bevacizumabhadalongermean
period of extension compared to ranibizumab. The treat-
and-extend regimen was associated with lower medical costs
when compared to the MARINA, ANCHOR, and PrONTO
protocols, with a reduced mean number of injections and
lower medical costs in the bevacizumab group [38].
6. Comparison of AMD Treatment
Trials (CATTs)
To compare the eﬃcacy of intravitreal injections of beva-
cizumab and ranibizumab and two dosing regimens,
monthly and as-needed with monthly evaluation, the Com-
parison of AMD Treatment Trials (CATTs) were initiated.
These multicenter, single-blind, noninferiority trials collec-
tivelyenrolled1208patientswithwetAMD.Retreatmentwas
performed if at least one of the following criteria was met:
ﬂuid present on time domain OCT, decreased VA as com-
pared to previous exam, new or persistent hemorrhage, or
dye leakage or increased lesion size on ﬂuorescein angiogra-
phy. The primary outcome measure was mean change in VA
at one year. After one year, there was no signiﬁcant diﬀerence
inVAoutcomesbetweenmonthlybevacizumabandmonthly
ranibizumab and between as-needed bevacizumab and as-
needed ranibizumab. Ranibizumab as-needed was found to
be equivalent to monthly ranibizumab, but the comparison
between bevacizumab as-needed and monthly bevacizumab
was inconclusive [39]. This could be due to the less durable
treatment eﬀect of bevacizumab in a subgroup of patients
[40].
The monthly ranibizumab regimen was associated with
the greatest decrease in OCT central retinal thickness. Al-
though not powered suﬃciently to compare adverse event
rates associated with the two drugs, the rates of death, arte-
riothrombotic events, and venous thrombotic events were
similar for patients receiving bevacizumab or ranibizumab.
The rate of serious systemic adverse events, primarily
hospitalizations, was higher among the patients who had
received bevacizumab, but rates of adverse events did not
increase with increased exposure to the drug [39].
Theresultsofthesecondyearofthetrialandthe5similar
trials currently being conducted in Europe may help to reﬁne
these data and could clarify lingering questions regarding
adverse events.
7. Management of Nonresponders
As many as 10% of patients can lose a signiﬁcant amount
of vision despite 2 years of monthly anti-VEGF therapy
[20, 21]. Within this group of individuals exist not only
those who progress to disciform scar, RPE rip, massive
subretinal hemorrhage, and geographic atrophy, but also
eyes that demonstrate persistent macular ﬂuid/blood and
leakage on ﬂuorescein angiography and vision loss. This
small subgroup of patients is commonly referred to as
anti-VEGF nonresponders. More aggressive forms of wet
AMD, including retinal angiomatous proliferation (RAP),
tachyphylaxis to anti-VEGF agents, mimics of wet AMD
[41], and underlying genetic diﬀerences among patients may
contribute to variability in anti-VEGF treatment response
[42, 43].
The therapeutic approach can be tailored in these pa-
tients to include alternating bevacizumab and ranibizumab
every 2 weeks to allow sustained anti-VEGF blockade,
or combination therapy including PDT and/or intravitreal
corticosteroids [41].
8.VEGFTrap-Eye
VEGF Trap-Eye (EYLEA; Regeneron, Tarrytown, NY, USA)
(VTE) is a soluble fusion protein consisting of 2 extracellular
cytokine receptor domains and a human Fc region of
immunoglobulin G (IgG). VEGF Trap-Eye includes speciﬁc
extracellular components of VEGF receptors 1 and 2 fused
to the constant region (Fc) of IgG1, resulting in 2 identical
arms, each constructed from segments of both VEGFR1
and VEGFR2 (Figure 2). These components were selected
based on their high aﬃnity for both VEGF-A and placental
growth factor (PlGF). The molecule uniquely binds both
ends of activated dimerized VEGF or PlGF between its arms,
preventing it from binding to the native receptors or cross-
linking. The binding aﬃnity of VEGF Trap to VEGF is 10
times higher than bevacizumab. The 2mg dose of VTE at 83
days has been proven to have a similar biologic activity to
ranibizumab at 30 days. The Fc portion likely plays a role in6 Journal of Ophthalmology
prolonging the half-life of the drug and could yield a longer
duration of action.
VIEW1 was a phase III noninferiority trial conducted in
NorthAmericathatrandomized1217patientstoVTE0.5mg
monthly dosing (0.5q4wk), VTE 2mg monthly (2q4wk),
VTE 2mg every two months following 3 monthly doses
(2q8wk), or ranibizumab 0.5mg monthly (Rq4wk). The
primary endpoint was the proportion of patients who lost
fewer than 15 ETDRS letters from baseline to week 52.
Secondary endpoints included mean change in BCVA at
week 52. The following percentage of participants in the
Rq4wk, 2q4wk, 0.5q4wk, and 2q8wk treatment arms gained
at least 15 letters: 31%, 38%, 25%, and 31%, respectively.
The proportions of patients maintaining vision at 52 weeks
were 94.4%, 95.9%, 95.1%, and 95.1% for Rq4wk, 0.5q4wk,
2q4wk, and 2q8wk, respectively. All VTE groups were non-
inferior to ranibizumab. Mean improvements from baseline
to week 52 in ETDRS letter score was 8.1, 6.9, 10.9, and 7.9
letters for Rq4wk, 0.5q4wk, 2q4wk, and 2q8wk, respectively.
2q4wk was associated with a signiﬁcantly greater mean
VA improvement from baseline to week 52 than Rq4wk.
Diﬀerences between other VTE groups and Rq4wk were
nonsigniﬁcant. The diﬀerence in the mean reduction in
central retinal thickness was not signiﬁcant among the
groups. The incidence of adverse events was similar across all
treatments, with no increase in blood pressure noted.
Overall, dosing monthly or every two months with VTE was
non-inferior to monthly ranibizumab and was well tolerated
[44]. The VIEW 2 study enrolled 1240 patients from Europe,
Latin America, Asia, and Australia and yielded similar results
[45].
9. Conclusions
Over the past two decades, the treatment of neovascular
AMD has been revolutionized with the discovery of anti-
VEGF agents that have enabled patients to regain vision
thought permanently lost to this potentially blinding disease.
With the goal of maximizing VA and minimizing the
frequency of intravitreal injections and associated risks of
treatment, evidence-based management of wet AMD has
evolvedintoindividualizedanti-VEGFtherapywithfrequent
followup and retreatment. As a safer, and more cost-eﬀective
alternative to the traditional monthly treatments used in
the ANCHOR and MARINA trials, two individualized anti-
VEGF treatment regimens have been described, but neither
has been proven superior to date: as-needed (or “prn”)
therapy and the treat-and-extend strategy. Despite a paucity
of evidence comparing the as-needed versus the treat-and-
extend treatment regimens, as the treat-and-extend regimen
is explored further, it could prove to be the most eﬃcacious,
cost-saving, and preferred protocol. The current evidence-
based treatment strategy for the management of wet AMD
supports the use of either bevacizumab or ranibizumab
either monthly or with a more individualized treatment
strategy with close followup. As second generation anti-
VEGF agents become available and the stress on our health-
care systems intensiﬁes, increasingly eﬃcacious and cost-
conscious treatment strategies will be essential.
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